Novartis Foresees Aclasta Approval By Year-End Despite Second "Approvable" Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is seeking additional information from ongoing osteoporosis trials of the zoledronic acid for treatment of Paget's disease.